The role and efficacy of Lenvatinib

In patients with differentiated thyroid cancer, lenvatinib showed clinically relevant improvements in the time patients lived without disease progression. Lenvatinib is as effective as sorafenib in extending life in patients with advanced hepatocellular carcinoma who have a poor prognosis and fewer treatment options. Likewise, lenvatinib plus pembrolizumab provides a valuable treatment option in patients with endometrial cancer that has failed to respond or relapses to platinum-based therapy.

In a syngeneic mouse tumor model, lenvatinib reduced tumor-associated macrophages, increased activated cytotoxic T cells, and showed greater anti-tumor activity in combination with an anti-PD-1 monoclonal antibody compared with treatment alone. The combination of lenvatinib and everolimus showed enhanced anti-angiogenic and anti-tumor activity, as demonstrated by a reduction in human endothelial cell proliferation, tube formation and VEGF signaling in vitro and a reduction in tumor volume in a mouse xenograft model of human renal cell cancer that was greater than either agent alone.

Lenvatinib The original drug has been launched in China and has entered the scope of Class B medical insurance. The price of 4mg*30 tablets per box may be more than 3,000 yuan. Lenvatinib original drug currently on the market overseas, specifications 4mg*30 capsules, may cost more than 1,000 yuan per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of a box of 4mg*30 tablets produced by a Bangladesh pharmaceutical factory may be around RMB 800 (the price may fluctuate due to exchange rates).